ADCs in focus: The next generation of precision medicine in oncology

Join the conversation with experts as they discuss the progress of antibody-drug conjugates (ADCs) in cancer treatment. They'll cover issues with early ADCs, how they work with immune therapies, and future targets and methods. Tempus supports ADC improvement by providing detailed genetic analysis, anonymous patient data, and AI tools to help find new targets and make clinical trials better for personalized treatments.